Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$4.94M$4.94M+12.3% vs Q3 2020 Net Income-$650.00K-$650.00KN/M vs Q3 2020 EPS Diluted-$0.32-$0.32N/M vs Q3 2020 Gross Profit$1,995,000−0.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived$746,000N/M Free Cash Flowderived$669,000N/M Margins · derivedGross margin40.4%−5.1 pt vs Q3 2020
Operating margin-2.8%+22.4 pt vs Q3 2020
Net margin-13.2%+11.5 pt vs Q3 2020
ended Dec 31, 2020 · filed Feb 16, 2021 · 47 d after period end